Trial reportPediatric nephrology (Berlin, Germany)2003
Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children.
Trial report in Pediatric nephrology (Berlin, Germany), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Annals of the rheumatic diseases · 2012Guideline
- Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2008Trial
- Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2005Trial
- IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes.International journal of molecular sciences · 2021Review
- The clinical effect of Prednisone in combination with Mycophenolate mofetil on idiopathic thrombocytopenic purpura (ITP) and its influence on the level of peripheral blood T lymphocytes and NK lymphocytes.Saudi journal of biological sciences · 2019Article
- Pharmacokinetic modeling of therapies for systemic lupus erythematosus.Expert review of clinical pharmacology · 2015Review
- How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Clinical pharmacokinetics · 2014Review
- Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.Clinical pharmacokinetics · 2013Review
- Graft loss due to recurrent disease in pediatric kidney transplant recipients on a rapid prednisone discontinuation protocol.Pediatric transplantation · 2012Article
- Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.Arthritis care & research · 2012Article
- Mycophenolate mofetil in juvenile dermatomyositis: a case series.Rheumatology international · 2012Article
- Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Mycophenolate mofetil monotherapy in the management of paediatric uveitis.Eye (London, England) · 2011Article
- The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.The Journal of clinical and aesthetic dermatology · 2011Article
- Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.Arthritis care & research · 2010Article
- Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease.Pediatric rheumatology online journal · 2010Article
- Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report.International journal of rheumatology · 2010Article
- Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.Pediatric nephrology (Berlin, Germany) · 2009Review
- Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.Pediatric nephrology (Berlin, Germany) · 2009Article
- Mycophenolate mofetil in the treatment of uveitis in children.The British journal of ophthalmology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study describes the pharmacokinetics of mycophenolate mofetil (MMF) in 15 pediatric patients with vasculitis and connective tissue disease involving the kidney. Patients included 10 with systemic lupus erythematosus (SLE), 1 with antiphospholipid antibody syndrome, 2 with Wegener granulomatosis, and 1 each with Goodpasture syndrome, Henoch-Schönlein-associated nephritis, and 1 with severe tubulointerstitial nephritis and uveitis. All patients were treated with steroids and additional therapy prior to treatment with MMF, which was administered for a median of 491 days. Mean starting dose of MMF was 974+/-282 mg/m(2 )in two divided doses. Pharmacokinetic monitoring of the active compound of MMF, mycophenolic acid (MPA), was performed using an EMIT assay. The mean MPA AUC after a median of 39 days was 61.8+/-31.0 micro gxh/ml, median time to maximum concentration was 60 min, and mean maximum concentration was 18.5+/-8.4 micro g/ml. At last follow-up, mean MMF dose was 900+/-341 mg/m(2) per day, and mean trough MPA concentration was 3.1+/-1.1 (range 0.6-4.6) micro g/ml. Therapy was effective in inducing remission in 4 of 9 patients with active disease. Only 1 of the 5 other patients relapsed. All 6 patients with controlled disease maintained remission. There were few side effects: one episode each of diarrhea and leukocytopenia and two viral infections. We conclude that MMF at 900 mg/m(2) per day appears to be effective in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.